Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 9Vomiting 5Nausea 5Lymphoma, Mantle-Cell 4Hodgkin Disease 4Breast Neoplasms 4Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Biphenotypic, Acute 3Immunoglobulin Light-chain Amyloidosis 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Hairy Cell 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1

Interventions

Rituximab 2dexamethasone acetate 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Opsoclonus-Myoclonus Syndrome × dexamethasone acetate × Clear all
NCT01868269 2025-02-03

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Institut Curie

Phase 3 Completed
102 enrolled
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡